Estimated Read Time:

1 minute

SABCS Snippets: Results from the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 trial

Richard C. Zellars, MD, talks with Jean Wright, MD, about the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 trial, which evaluated the impact of tamoxifen only after breast conservation surgery for “good risk” ductal carcinoma in situ.

Share

Recent Posts

Upcoming Industry Events

View Calendar
View All